FI57260C - Foerfarande foer framstaellning av terapeutiskt verksamma 2-amino-3,4-dihydro-5-metyl-imidazo-/5,1-f/-as-triaziner - Google Patents

Foerfarande foer framstaellning av terapeutiskt verksamma 2-amino-3,4-dihydro-5-metyl-imidazo-/5,1-f/-as-triaziner Download PDF

Info

Publication number
FI57260C
FI57260C FI3900/73A FI390073A FI57260C FI 57260 C FI57260 C FI 57260C FI 3900/73 A FI3900/73 A FI 3900/73A FI 390073 A FI390073 A FI 390073A FI 57260 C FI57260 C FI 57260C
Authority
FI
Finland
Prior art keywords
group
carbon atoms
dihydro
amino
substituted
Prior art date
Application number
FI3900/73A
Other languages
English (en)
Finnish (fi)
Other versions
FI57260B (fi
Inventor
Robert William Clarke
David Hartley
Alexander William Oxford
Original Assignee
Allen & Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen & Hanburys Ltd filed Critical Allen & Hanburys Ltd
Priority to FI793137A priority Critical patent/FI793137A/fi
Application granted granted Critical
Publication of FI57260B publication Critical patent/FI57260B/fi
Publication of FI57260C publication Critical patent/FI57260C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI3900/73A 1973-01-04 1973-12-18 Foerfarande foer framstaellning av terapeutiskt verksamma 2-amino-3,4-dihydro-5-metyl-imidazo-/5,1-f/-as-triaziner FI57260C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI793137A FI793137A (fi) 1973-01-04 1979-10-10 Foerfarande foer framstaellning av terapeutiskt verksamma 2-amino-3-hydro-imidazotriaziner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB55373*[A GB1457873A (en) 1973-01-04 1973-01-04 Imidazotriazines
GB55373 1973-01-04

Publications (2)

Publication Number Publication Date
FI57260B FI57260B (fi) 1980-03-31
FI57260C true FI57260C (fi) 1980-07-10

Family

ID=9706420

Family Applications (1)

Application Number Title Priority Date Filing Date
FI3900/73A FI57260C (fi) 1973-01-04 1973-12-18 Foerfarande foer framstaellning av terapeutiskt verksamma 2-amino-3,4-dihydro-5-metyl-imidazo-/5,1-f/-as-triaziner

Country Status (19)

Country Link
US (1) US3941785A (ja)
JP (1) JPS4995994A (ja)
AT (1) AT336029B (ja)
AU (1) AU474078B2 (ja)
BE (1) BE809369A (ja)
CA (1) CA1005057A (ja)
CH (1) CH618170A5 (ja)
DE (1) DE2364076A1 (ja)
ES (1) ES422001A1 (ja)
FI (1) FI57260C (ja)
FR (1) FR2213058B1 (ja)
GB (1) GB1457873A (ja)
IE (1) IE38681B1 (ja)
IL (1) IL43872A (ja)
LU (1) LU69099A1 (ja)
NL (1) NL7400095A (ja)
NO (1) NO140301C (ja)
SE (1) SE408179B (ja)
ZA (1) ZA739534B (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4096257A (en) * 1977-05-23 1978-06-20 American Cyanamid Company Substituted imidazo [1,2-d]-as-triazines
US4107309A (en) * 1977-05-23 1978-08-15 American Cyanamid Company Substituted imidazo[1,2-d]-as-triazines
US4126444A (en) * 1977-11-22 1978-11-21 American Cynamid Company Substituted imidazo (1,5-D)-as-triazin-4-ols, and herbicidal use thereof
US4308384A (en) * 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
DD244681A3 (de) * 1985-12-02 1987-04-15 Zeiss Jena Veb Carl Vorrichtung zur positionierung von enden flexibler lichtleitelemente
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
GB2346877B (en) 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
CA2341488A1 (en) 1998-08-26 2000-03-09 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
AU777012B2 (en) * 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
ATE348618T1 (de) * 2001-05-09 2007-01-15 Bayer Healthcare Ag Neue verwendung von 2-(2-ethoxy-5-(4-methyl- piperazin-1-sulfonyl)-phenyl)-5-methyl-7-propyl 3h-imidazo(5,1-f)(1,2,4)triazin-4-on
GB0113344D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
EP1608656B1 (en) * 2003-04-01 2009-06-03 SmithKline Beecham Corporation Imidazotriazine compounds for the treatment of cancer diseases
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
WO2008036678A2 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2167057A1 (en) * 2007-06-13 2010-03-31 Bayer HealthCare AG Pde inhibitors for the treatment of hearing impairment
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques

Also Published As

Publication number Publication date
FR2213058A1 (ja) 1974-08-02
BE809369A (fr) 1974-07-03
ES422001A1 (es) 1976-08-01
DE2364076A1 (de) 1974-07-18
ATA2374A (de) 1976-08-15
IL43872A0 (en) 1974-03-14
NO140301B (no) 1979-04-30
CA1005057A (en) 1977-02-08
FR2213058B1 (ja) 1977-07-01
SE408179B (sv) 1979-05-21
GB1457873A (en) 1976-12-08
CH618170A5 (ja) 1980-07-15
NL7400095A (ja) 1974-07-08
LU69099A1 (ja) 1974-04-02
JPS4995994A (ja) 1974-09-11
IL43872A (en) 1979-01-31
NO140301C (no) 1979-08-08
IE38681L (en) 1974-07-04
AU474078B2 (en) 1976-07-15
AT336029B (de) 1977-04-12
FI57260B (fi) 1980-03-31
ZA739534B (en) 1974-11-27
AU6377473A (en) 1975-06-19
IE38681B1 (en) 1978-05-10
US3941785A (en) 1976-03-02

Similar Documents

Publication Publication Date Title
FI57260C (fi) Foerfarande foer framstaellning av terapeutiskt verksamma 2-amino-3,4-dihydro-5-metyl-imidazo-/5,1-f/-as-triaziner
US3812127A (en) 4-(quinolin-4-yl)piperazine-1-carboxylic acid esters
FI78097B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara (2-oxo-1,2,3,5-tatrahydroimidazo/2,1-b/ kinazolinyl)oxialkylamider.
Daly et al. Analogs of caffeine and theophylline: Effect of structural alterations on affinity at adenosine receptors
US3702849A (en) 4-(isoquinolin-1-yl) piperazine-1-carboxylic acid esters
EP0591528B1 (en) PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
US4289776A (en) Xanthine derivatives
US5866580A (en) Quinazoline derivatives and methods of using the same
CZ342595A3 (en) Purine derivatives, process of their preparation and pharmaceutical compositions containing thereof
PL212407B1 (pl) Zwiazek pochodny 8-chinolinoksantyny i 8-izochinolinoksantyny, jego zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazek oraz sposób wytwarzania zwiazku
US4783530A (en) 8-arylxanthines
NO134212B (ja)
US4276295A (en) 3-Aromatic moiety substituted-4(3H)-quinazolinones, process for production thereof, and use thereof
Sakai et al. Effects of alkyl substitutions of xanthine skeleton on bronchodilation
Novinson et al. Adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors. 2. 3-Substituted 5, 7-dialkylpyrazolo [1, 5-a] pyrimidines
US4822800A (en) Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US5314890A (en) 1-7 disubstituted xanthine derivatives having antiasthmatic activity, their physiologically acceptable salts, pharmaceutical compositions containing them and process for their preparation
US5342841A (en) Xanthine derivatives
US4801590A (en) Pyrido(1,8)naphthyridinones, and their use as pharmaceuticals
Sinha et al. Synthesis and antitumor properties of bis (quinaldine) derivatives
US5278186A (en) Chromene derivatives, their production and use
US5378844A (en) 8-(1-aminocycloalkyl)-1,3-dialkylxanthine derivatives, preparation process and antidepressant, nootropic and psychostimulant composition thereoff
US4176183A (en) Novel naphthyridines
US6114339A (en) Derivatives of pyrido [2,3-D] and [3,2-D] pyrimidine method of using these derivatives
DD236523A5 (de) Verfahren zur herstellung von chinolon- und naphtyridoncarbonsaeuren